Clinical Trial Update: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of alectinib in ALK-positive NSCLC patients who failed crizotinib; trial completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small-Cell Lung Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-05-26